Story perspectives

NSCLC Market Set for Growth Amid Treatment Innovations

9/10/2025

Summary

Story summary

The non-small cell lung cancer (NSCLC) market is projected to grow steadily from 2025 to 2035, driven by rising incidence and advancements in biomarker-based treatments.
Key players include Merck, Bristol Myers Squibb, Roche, and AstraZeneca.
NSCLC, the most common lung cancer type, has subtypes like adenocarcinoma and squamous cell carcinoma.
Major risk factors are smoking and environmental exposures.
Innovations include immune checkpoint inhibitors, CAR-T cell therapies, and increased use of companion diagnostics and liquid biopsy methods.

1 of 1

Story summary

The non-small cell lung cancer (NSCLC) market is projected to grow steadily from 2025 to 2035, driven by rising incidence and advancements in biomarker-based treatments.
Key players include Merck, Bristol Myers Squibb, Roche, and AstraZeneca.
NSCLC, the most common lung cancer type, has subtypes like adenocarcinoma and squamous cell carcinoma.
Major risk factors are smoking and environmental exposures.
Innovations include immune checkpoint inhibitors, CAR-T cell therapies, and increased use of companion diagnostics and liquid biopsy methods.